US FDA action on unapproved codeine will not hit Glenmark's financials, firm says
This article was originally published in Scrip
Executive Summary
The US FDA's recent warning to four companies asking them to stop marketing unapproved codeine sulphate tablets is expected to have no significant impact on Glenmark's financial performance, the firm said.